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ORIGINAL ARTICLE
Clinical characteristics and patient treatment satisfaction with Humalog U-200 in
patients with type 2 diabetes mellitus: an observational study
Jil Mamza, Uchena Anyanwagu, Mohammed Alkharaiji and Iskandar Idris
Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK
ABSTRACT
Background: There are limited data on the real-world evidence of Humalog 200 units/ml KwikPen (U-
200) insulin. We assessed the use of U-200 insulin in UK routine clinical practice to provide information
on clinical characteristics, treatment satisfaction and short-term clinical outcomes.
Methods: Nine patients with type 2 diabetes who initiated U-200 in secondary care and a further 12
identified from primary care electronic database were enrolled. A treatment satisfaction questionnaire
was administered to the 19 secondary care patients. Follow-up data on clinical parameters were col-
lected at 3 and 6months following initial U-200 insulin administration and the data were used to
assess changes in clinical outcomes from baseline.
Results: Secondary care patients had a mean age 60±11 years, mean HbA1c of 8.6%±1.3% and a
mean BMI of 39.7 ±5.3 kg/m2 at baseline. Primary care database patients had a mean age 57±13 years,
mean HbA1c 10.3%±1.7 and a mean BMI 42.3 ±3.8 kg/m2. The nine participants’ responses to the
questionnaire suggested a high preference for U-200 over a previous mealtime insulin pen (PMIP). On
average, the patients agreed that U-200 was quicker to inject, had a better controlled home blood glu-
cose reading and less discomfort at the injection site compared to a PMIP. Patients were willing to
continue with their U-200 treatment. No significant HbA1c reduction was observed at 3months in the
secondary care group (0.5%), but marked significant reduction in HbA1c was seen at 3months in
the primary care dataset to (2.8%; p< .0004). There was also some suggestion of weight loss in both
the secondary and primary care groups.
Conclusion: Humalog U-200 insulin users were comprised mainly of older patients with diabetes com-
plications and high HbA1c levels at the time of U-200 initiation. Overall, U-200 improved patients’ sat-
isfaction with diabetes treatment and short-term metabolic outcomes.
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Introduction
Insulin lispro 200 units/ml (Humalog U-200 KwikPen) is a
concentrated rapid-acting insulin analog bio- and therapeut-
ically equivalent to the 100 units/ml Humalog formulation1.
However, U-200 KwikPen holds 600 total units of insulin in
the same sized pen that previously could only hold 300 total
units. Specific advantages of U-200 compared with conven-
tional U-100 insulin include less volume for injection result-
ing in an easier glide force for injection2. Given the
importance of simplifying insulin injection3 by using less vol-
ume and less force required for injection, it is hypothesized
that the use of Humalog U-200 may contribute to improving
treatment adherence and, consequently, metabolic control.
Additionally, since each pen last longer, patients will not be
required to request repeat prescription as frequently, which
would ensure less risks of missing injections due to pen run-
ning out of insulin. Although, Humalog U-200 is a practical
alternative regimen to people with diabetes who take higher
doses of rapid-acting (e.g. >0.5 units/kg), post-marketing sur-
veillance or real-world evidence assessing the use of U-200
insulin in routine practice is lacking.
Factors that may explain insulin treatment failure, include
complex diabetes regime, polypharmacy, side effects, thera-
peutic inertia and non-adherence4. In addition, incorrect
insulin administration techniques and pen misuse5 may
greatly affect metabolic control in patients on multiple daily
injections. Routine clinical practice provides a useful source
of data for evaluating clinical effectiveness, but to date, no
real-world study in the UK has described the clinical charac-
teristics of patients administering Humalog U-200 and the
extent to which patients are satisfied with their diabetes
treatment. Therefore, we examined the clinical characteristics
of patients who were administered Humalog U-200 insulin in
routine clinical practice and to describe using questionnaires,
patients’ perceptions of their diabetes treatment following
the use of Humalog U-200 KwikPen, compared with their
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previous mealtime insulin pen (PMIP) of >3months duration.
The study also used anonymized health records of randomly
recruited patients in UK primary care between July and
September 2017. In addition, the study analyzed their follow-
up clinical parameters’ data at 3 and 6 months following ini-
tial administration.
Methods
Study design and setting
This was an observational study using anonymized medical
records of adult patients (aged >18 years) who administered
Humalog U-200 in UK clinical practice. Clinical parameters of
patients were collected from five secondary care centers in
the UK. Follow-up data on clinical parameters were collected
at 3 and 6months following initial Humalog U-200 adminis-
tration. A further 12 patients who were commenced on
Humalog U-200 was identified from the Health Improvement
Network, a primary care electronic database. A questionnaire
was administered to nine individual patients by post or by
face-to-face meeting to investigate their experience of using
Humalog U-200 and their satisfaction with their diabetes
treatment following U-200 treatment initiation. Patients did
not receive any reimbursement for their contribution to
the study.
Demographic and clinical parameters
The baseline demographic and clinical parameters were
selected a priori on the basis of clinical significance and
included in the descriptive analyses. These include age at ini-
tial U-200 treatment, gender, ethnic background, type of dia-
betes, duration of diabetes, body weight and medications
were included in the data collection. Microsoft Access was
used to collect anonymized data from secondary care
patients. Information on complications such as stroke, per-
ipheral artery disease, retinopathy, nephropathy and neur-
opathy were also assessed. Data were collated on clinical
parameters at baseline, at the third and at the sixth months
following the commencement of U-200 insulin. Information
on patients’ antidiabetic therapy including insulin administra-
tion at baseline, and at the third and sixth months following
U-200 treatment initiation were assessed. Comparison of the
changes in patients’ glycemic hemoglobin (HbA1c) and
weight, body mass index (BMI), at baseline and at 3 and
6months post-Humalog U-200 insulin treatment initiation
were calculated.
Treatment experience and satisfaction survey
The patient confidence and satisfaction survey were
designed by the current study investigators in accordance
with NHS guidelines or recommendations available from
www.nhssurveys.org. Participants completed this by mail at a
minimum of 3months after starting U-200. The questionnaire
comprised two main sections. The first (Q2) described short
statements relating to the patients’ experience of the
Humalog U-200 in comparison to their PMIP following the
commencement of Humalog U-200. The second (Q3) section
described statements relating to patients’ satisfaction with
their diabetes treatment following the initiation of Humalog
U-200 insulin treatment. For each of the statements, patients
were asked to rate their level of preference by choosing
from a 5-point Likert scale option ranging from “strongly dis-
agree” to “strongly agree”. Data on individual patient’s
response to the survey were collected using paper question-
naires. The survey information and descriptions of statements
are included in Supporting Information I.
Data analyses
The characteristics and clinical parameters of the patients are
summarized using descriptive statistics. A simple paired t-test
was used to measure change in the means HbA1c and
weight at 3months and 6months after administering
Humalog U-200 compared to the baseline measurements.
Analysis was conducted separately for primary care and sec-
ondary care cohort due to different information being avail-
able for both cohorts and because the main of this work is
to explore treatment satisfaction outcomes The variability in
the extent to which patient responded to the questionnaires
was assessed across each of the statements presented to the
patients in the survey. Threshold for statistical significance
was p< .05. Statistical calculations were performed using
Stata 14.
Details of ethics approval
The study was approved by London – West London & GTAC
Research Ethics Committee.
Results
Clinical characteristics
Table S1 (see Supplementary Appendix 3) summarizes the
baseline values of secondary care patient and clinical charac-
teristics for nine patients whose medical care records were
collected. All the patients were Caucasian with a mean age
of approximately 60 ± 11) years, and comprised of predomin-
antly men (89%, n¼ 8). The average HbA1c at baseline was
8.6%±1.3% and their average BMI was 39.7 ± 5.3) kg/m2 at
baseline. Over half of the patients (56%) had a known dia-
betes complication at baseline and 22% had hypoglycemia
unawareness. Specific complications recorded at baseline
include CHD (22%), retinopathy (44%), nephropathy (56%)
and neuropathy (44%). Thirty-three percent of patients
received a intermediate and long-acting insulin, whereas
22% received a short-acting insulin therapy as their first insu-
lin regimen. The remaining patients received biphasic insulin
previously. Forty-four percent administered U-200 insulin
three times daily on commencement. There was one patient
recorded to have had U-200 insulin once a day and another
one patient recorded to have had U-200 up to four times a
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day. Overall, the average daily dose of U-200 insulin was
approximately 154.3 ± 104.1.
Within the primary care dataset, 3 out of the 12 who
were using Humalog U-200 KwikPen were male (25%). The
mean age at baseline was 57.0 ± 12.9. The average HbA1c at
baseline 10.3%±1.7 and an average BMI of 42.3 ± 3.8 kg/m2.
Seven patients were found to be using rapid-acting insulin
prior to the introduction of Humalog U-200. Four of these
patients used rapid-acting insulin as part of a basal-
bolus regimen.
User experience and satisfaction
Figure 1 illustrates the variability in the experiences of
patients who used Humalog U-200 KwikPen. Overall, the
patients’ responses to the questionnaire showed a high pref-
erence for Humalog U-200 KwikPen over a PMIP. Patients
found it quicker to inject with U-200 KwikPen than with a
PMIP and perceived their home blood glucose reading was
better controlled since starting Humalog U-200 KwikPen.
Figure 2 describes the differences in the extent to which
patients were satisfied with their diabetes treatment after ini-
tiating therapy with U-200 KwikPen. The extent to which
patients were satisfied with their current diabetes treatment
was on average 4.2 on a 5-point scale, and were satisfied to
continue with their present form of treatment (average score
¼ 4.3).
Short-term clinical outcomes
HbA1c
In the secondary care group, the average HbA1c was lower
at all time points during the follow-up period compared to
baseline; with no statistically significant difference. At 3
months, the mean HbA1c had reduced by 0.5% compared to
the baseline, and the reduction remained at 0.5% at 6
months (p value ¼ .5).
In the primary care dataset, HbA1c was lower at all time
points during the follow-up period compared to baseline;
with only a statistically significant difference at the 3-month
stage. At 3 months, the mean HbA1c was 7.5%± 1.5 with a
reduction of 2.8%l compared to the baseline (p¼ .0004).
Mean HbA1c at 6months was 9.0%± 0.4 (p¼ .094)
Body weight
In the secondary care group, the mean weight at baseline
was 117.9 (SD ± 18.3) kg and the calculated mean BMI was
Figure 2. Patient satisfaction of diabetes treatment using U-200 insulin (Supplementary Appendix 2). It shows the variability in the response scores given by all
nine respondents for the statements in Supplementary Appendix 2 of the questionnaire in Supplementary Information I. The range plots (horizontal bars) represent
the 25th and 75th percentile of the mean score. Abbreviations. U-200 KP, Humalog 200 units/ml KwikPen; PMIP, previous mealtime insulin pen.
Figure 1. Response to questionnaire on user experience survey (Supplementary Appendix 1). It shows the variability in the response scores given by all nine
respondents for the statements in Supplementary Appendix 1 of the questionnaire in Supplementary Information I. The range plots (horizontal bars) represent the
25th and 75th percentile of the mean score. Abbreviations. U-200 KP, Humalog 200 units/ml KwikPen; PMIP, previous mealtime insulin pen.
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38.7 ± 5.3 kg/m2. Mean weight at 6months was 104.3 ± 4 kg/
m2. This was observed to be 13.6 kg lower at 6months (there
was no weight measurement at 3months) compared to the
baseline, however, the reduction in body weight was not
statistically significant.
In the primary care dataset, the mean weight at baseline
is 117.1 ± 11.1 kg and the calculated mean BMI was
42.3 ± 3.9 kg/m2. Both weight and BMI were found to be
lower at all time points from baseline onwards, with only
one statistically significant difference at 3 months. The mean
weight at 3 months 101.2 ± 16.9 kg revealed a reduction of
16.0 kg compared to the baseline (p¼ .007). Mean weight at
6months, however, was 111.7 (p¼ .54).
Discussion
Main findings
On average, the patients perceived U-200 insulin was quicker
to inject, had a better controlled home blood glucose read-
ing and less discomfort at the injection site compared to a
PMIP. The patients’ response to the questionnaire suggested
they had a strong preference for U-200 over a PMIP and
were willing to continue with their U-200 treatment.
Metabolic results from this study also indicate a short-term
benefit of U-200 in reducing HbA1c and other clinical param-
eters of interest including weight. Whether the reduction in
weight induced reduction on Hba1c or vice versa is unclear
and is outside the remit of this study, but we believe these
parameters are codependent.
Our findings support findings from a previous study from
Italy which indicated a positive treatment satisfaction from
most patients, which translated to improved short-term
HbA1c levels. Interestingly, in that study, there was a dosage
reduction of Humalog U-200 and reduction in the risk of
hypoglycemia6. Our study did not show this, likely due to
the small number of patients who use this insulin formula-
tion. Nonetheless, the advantages of less injection effort with
Humalog U-200 in our study support previous studies where
volume reduction will result in less force to be applied to
the pen7–9. This may translate to improved HbA1c level,
although such broad conclusions cannot be made from our
study due to the small number. However, due to the high
prevalence of limited joint mobility in patients with dia-
betes10,11, the ease of injection may help many patients to
deliver their insulin more safely and effectively. Furthermore,
it is tempting to speculate that less injection volumes will
prevent wastage of insulin, conferring long-term eco-
nomic benefits.
Strengths and limitations
To our knowledge, this study is the first observational study
on the clinical outcomes of Humalog U-200 KwikPen in the
UK. This study is strengthened by data providing real-world
evidence from routine clinical care. Given that this study
examined short-term clinical outcomes, it is understandable
that the patient who initiated insulin treatment with
Humalog U-200 will have very high expectations for their
metabolic outcomes. Of note, however, these patients are
older with high Hba1c at baseline – suggesting more compli-
cated patients with type 2 diabetes. Major limitations of this
study include the short duration of follow-up observations
and the small number of patients involved. Another limita-
tion includes the possibility that the questionnaires may not
have accounted for the entire experience a patient might
have had while using U-200 KwikPen, due to recall bias, the
fact that these are un-validated questionnaires and lack of
information of fasting and post-prandial glucose hemo-
dynamics as well as hypoglycemia events. Nevertheless, pre-
liminary findings from the study show that Humalog U-200
reduced, HbA1c and possibly weight within 3–6months of
treatment initiation and such favorable metabolic results in
combination with ease of use provide objective support to
patients’ preference ratings.
Conclusion
To conclude, Humalog U-200 is an appropriate therapeutic
option for patients with type 2 diabetes who require insulin
treatment to manage their hyperglycemia. Its use was associ-
ated with short-term reduction in Hba1c and weight with
favorable effects on treatment satisfaction. The use of lower
injection volume and ease of slide may benefit patients with
limited joint mobility or those who are on high doses of
insulin. This study also underscores the importance of further
studies in clinical decision-making on individualized pen
devices to improve treatment compliance and gly-
cemic control.
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